Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment
Background ::: In this study we compare the Omalizumab treatment modality in the dynamics of cell apoptosis regulating molecules in both severe persistent asthma patients who had no other any allergic disease, newly diagnosed patients with allergic asthma, and healthy volunteers.
Object of the present invention to provide a granular preparation hours even in average particle diameter, can be effectively controlled drug dissolution characteristics. The present invention provides a granule formulation, wherein that the first coating layer containing a water-insoluble polymer particles and inorganic particles and granular formulations of a drug having a first cladding layer of the coated drug particles and / or lipid components, the lipid component contains more C15 fatty acids.